213 related articles for article (PubMed ID: 25622007)
1. Structural basis of new allosteric inhibition in Kinesin spindle protein Eg5.
Yokoyama H; Sawada J; Katoh S; Matsuno K; Ogo N; Ishikawa Y; Hashimoto H; Fujii S; Asai A
ACS Chem Biol; 2015 Apr; 10(4):1128-36. PubMed ID: 25622007
[TBL] [Abstract][Full Text] [Related]
2. An allosteric transition trapped in an intermediate state of a new kinesin-inhibitor complex.
Kaan HY; Ulaganathan V; Hackney DD; Kozielski F
Biochem J; 2009 Dec; 425(1):55-60. PubMed ID: 19793049
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Biphenyl-Type Inhibitors Targeting the Eg5 α4/α6 Allosteric Pocket.
Gao C; Lowndes NF; Eriksson LA
ACS Omega; 2017 May; 2(5):1836-1849. PubMed ID: 30023646
[TBL] [Abstract][Full Text] [Related]
4. Structural insights into a unique inhibitor binding pocket in kinesin spindle protein.
Ulaganathan V; Talapatra SK; Rath O; Pannifer A; Hackney DD; Kozielski F
J Am Chem Soc; 2013 Feb; 135(6):2263-72. PubMed ID: 23305346
[TBL] [Abstract][Full Text] [Related]
5. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5.
Brier S; Lemaire D; Debonis S; Forest E; Kozielski F
Biochemistry; 2004 Oct; 43(41):13072-82. PubMed ID: 15476401
[TBL] [Abstract][Full Text] [Related]
6. Disparity in allosteric interactions of monastrol with Eg5 in the presence of ADP and ATP: a difference FT-IR investigation.
Wojcik EJ; Dalrymple NA; Alford SR; Walker RA; Kim S
Biochemistry; 2004 Aug; 43(31):9939-49. PubMed ID: 15287721
[TBL] [Abstract][Full Text] [Related]
7. STLC-resistant cell lines as tools to classify chemically divergent Eg5 targeting agents according to their mode of action and target specificity.
Indorato RL; DeBonis S; Kozielski F; Garcia-Saez I; Skoufias DA
Biochem Pharmacol; 2013 Nov; 86(10):1441-51. PubMed ID: 24041742
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel scaffolds to inhibit human mitotic kinesin Eg5 targeting the second allosteric binding site using in silico methods.
Makala H; Ulaganathan V
J Recept Signal Transduct Res; 2018 Feb; 38(1):12-19. PubMed ID: 29041840
[TBL] [Abstract][Full Text] [Related]
9. Exploring the intermediate states of ADP-ATP exchange: a simulation study on Eg5.
Zhang W
J Phys Chem B; 2011 Feb; 115(5):784-95. PubMed ID: 21192710
[TBL] [Abstract][Full Text] [Related]
10. Nucleotide-dependent movements of the kinesin motor domain predicted by simulated annealing.
Wriggers W; Schulten K
Biophys J; 1998 Aug; 75(2):646-61. PubMed ID: 9675167
[TBL] [Abstract][Full Text] [Related]
11. Discovery and biochemical characterization of selective ATP competitive inhibitors of the human mitotic kinesin KSP.
Rickert KW; Schaber M; Torrent M; Neilson LA; Tasber ES; Garbaccio R; Coleman PJ; Harvey D; Zhang Y; Yang Y; Marshall G; Lee L; Walsh ES; Hamilton K; Buser CA
Arch Biochem Biophys; 2008 Jan; 469(2):220-31. PubMed ID: 17999913
[TBL] [Abstract][Full Text] [Related]
12. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5.
Maliga Z; Kapoor TM; Mitchison TJ
Chem Biol; 2002 Sep; 9(9):989-96. PubMed ID: 12323373
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship of pyrazolo pyrimidine derivatives as inhibitors of mitotic kinesin Eg5 and anticancer agents.
Muthuraja P; Veeramani V; Prakash S; Himesh M; Venkatasubramanian U; Manisankar P
Bioorg Chem; 2019 Mar; 84():493-504. PubMed ID: 30594885
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of the Eg5 - K858 complex and implications for structure-based design of thiadiazole-containing inhibitors.
Talapatra SK; Tham CL; Guglielmi P; Cirilli R; Chandrasekaran B; Karpoormath R; Carradori S; Kozielski F
Eur J Med Chem; 2018 Aug; 156():641-651. PubMed ID: 30031975
[TBL] [Abstract][Full Text] [Related]
15. Kinesin-5 allosteric inhibitors uncouple the dynamics of nucleotide, microtubule, and neck-linker binding sites.
Scarabelli G; Grant BJ
Biophys J; 2014 Nov; 107(9):2204-13. PubMed ID: 25418105
[TBL] [Abstract][Full Text] [Related]
16. "Snapshots" of ispinesib-induced conformational changes in the mitotic kinesin Eg5.
Kaan HY; Major J; Tkocz K; Kozielski F; Rosenfeld SS
J Biol Chem; 2013 Jun; 288(25):18588-98. PubMed ID: 23658017
[TBL] [Abstract][Full Text] [Related]
17. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents.
Brier S; Lemaire D; DeBonis S; Forest E; Kozielski F
J Mol Biol; 2006 Jul; 360(2):360-76. PubMed ID: 16780877
[TBL] [Abstract][Full Text] [Related]
18. Binding patterns of inhibitors to different pockets of kinesin Eg5.
Jia N; Zhang B; Huo Z; Qin J; Ji Q; Geng Y
Arch Biochem Biophys; 2024 Jun; 756():109998. PubMed ID: 38641233
[TBL] [Abstract][Full Text] [Related]
19. Significant decrease of ADP release rate underlies the potent activity of dimethylenastron to inhibit mitotic kinesin Eg5 and cancer cell proliferation.
Sun L; Sun X; Xie S; Yu H; Zhong D
Biochem Biophys Res Commun; 2014 May; 447(3):465-70. PubMed ID: 24732354
[TBL] [Abstract][Full Text] [Related]
20. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5.
DeBonis S; Simorre JP; Crevel I; Lebeau L; Skoufias DA; Blangy A; Ebel C; Gans P; Cross R; Hackney DD; Wade RH; Kozielski F
Biochemistry; 2003 Jan; 42(2):338-49. PubMed ID: 12525161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
